Probing Cancer: Immunotherapy and Molecular Imaging

Dr Robins researches novel immune checkpoint inhibitor (ICI) therapies.

The Singapore-based Cancer ImmunoTherapy Imaging (CITI) programme is a Singapore-wide collaborative research group, comprising 12 research institutes. CITI’s efforts are focused on the discovery and application of peptide-based imaging probes, which target immunotherapy treatment response biomarkers. Dr Edward G Robins, Head of Radiochemistry at the Singapore Bioimaging Consortium and Deputy Director of the NUS Clinical Imaging Research Centre, alongside his […]

Read More…

A new weapon to boost cancer immunotherapy

The 4SC team monitors the expression of relevant genes in the tumours of patients before and after administration of domatinostat.

In recent years, immunooncology has paved new avenues for effective treatment across cancer types. In addition to cytotoxic chemotherapy, we can now harness the power of the human immune response against malignant cells. However, immunotherapy is not perfect, and as always, cancer has mechanisms to evade these attacks. Dr Svetlana Hamm, Head of Research and Translational Medicine at 4SC in […]

Read More…

Transtympanic injections to prevent hearing loss caused by cisplatin

Combination therapies with an otoprotectant may help to prevent hearing loss caused by chemotherapeutic agent cisplatin.

Dr Sofia Waissbluth from The Pontificia Universidad Católica de Chile is specialised in otolaryngology (conditions of the head and neck). She has reviewed clinical trials that use transtympanic injections to prevent hearing loss caused by the chemotherapeutic agent cisplatin. To date there is no ‘one-shot’ solution to protect or cure patients from hearing loss. However, combinational therapy using transtympanic injections […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION